Threshold eyes Ph III pancreatic trials for TH-302 despite OS significance miss
This article was originally published in Scrip
Threshold Pharmaceuticals' stock price fell 19.7% on 17 September after it reported Phase IIb median overall survival (OS) data that were positive yet not statistically significant for the tumour hypoxia-targeting small molecule TH-302 in the treatment of pancreatic cancer. But a spokeswoman for the company said the clinical trial results nevertheless supported Phase III development.
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.